InvestorsHub Logo

Horseb4CarT

01/16/24 10:32 PM

#664690 RE: hoffmann6383 #664685

As previously posited, non acceptance would have been made public by now imo, therefore acceptance/validation is a tacit assumption at this point logically.

manibiotech

01/16/24 10:46 PM

#664694 RE: hoffmann6383 #664685

“Most” public companies also do lot of things regularly

ilovetech

01/16/24 10:54 PM

#664699 RE: hoffmann6383 #664685

Hoffman -

It's illogical message board dot connecting where people are twisting words to hear what they want to hear.


Yup, that pretty much sums it up. 🎯

CrashOverride

01/16/24 11:56 PM

#664709 RE: hoffmann6383 #664685

Never been happier owning Northwest Biotherapeutics.

Never sold.

Never will.
Bullish
Bullish

DocLee

01/17/24 2:02 AM

#664720 RE: hoffmann6383 #664685

Interesting resource (Bard) that you posted.

Thanks

Springbok80

01/17/24 6:50 AM

#664744 RE: hoffmann6383 #664685

My opinion is that it all is just to stir the pot and that some "longs" are also trying to play the short game for a while, offsetting their long losses, and are doing all they can to ensure the price goes down. Again, just my opinion.

Margin Buu

01/17/24 7:19 AM

#664748 RE: hoffmann6383 #664685

Thank you Hoffmann. There’s nothing left to do but wait for MAA APPROVAL. Period. Some people don’t want the clock to start but this is in the hands of the regulating authority.

What a monumental achievement by NWBO to make it to this milestone. Looking forward to a relatively swift approval by MHRA. GBM patients need this to be covered by insurance.

Exciting, from their last PR Dec 21st, GBM treatment is only the beginning:


The Company believes that this mechanism of action will be applicable for most types of solid tumors. Solid tumors comprise approximately 90% of all cancers, and a key difficulty that other treatment approaches have encountered with solid tumors is their heterogeneity.

The Company has already had positive results with DCVax-L in some compassionate use cases with other diverse solid tumors. The Company looks forward to building on its experience with DCVax-L in GBM and the compassionate use cases to address a wide range of other operable solid tumors.

Bullish
Bullish